Jan Panteli

Title: Jan Panteli: Innovator in Transfection Reagents and Viral Vector Production

Introduction

Jan Panteli is an accomplished inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of methods for producing transfection reagents and enhancing viral vector yields. With a total of 2 patents, Panteli's work is paving the way for advancements in genetic engineering and therapeutic applications.

Latest Patents

Jan Panteli's latest patents include innovative methods that address critical challenges in biotechnology. The first patent, titled "Scalable method for producing transfection reagents," provides easy-to-scale methods of creating DNA/transfection reagent master mixes for transfecting cells in culture. This invention simplifies the process of preparing transfection reagents, making it more accessible for researchers. The second patent, "Use of tonicifying agents to enhance recombinant adeno-associated virus yield," outlines methods for producing recombinant adeno-associated virus vectors (rAAV). This invention involves culturing producer cells in media with increased osmolality, which not only enhances the yield of rAAV but also reduces the production of helper viruses.

Career Highlights

Jan Panteli is currently employed at Ultragenyx Pharmaceutical Inc., where he continues to innovate in the field of biotechnology. His work focuses on developing solutions that improve the efficiency and effectiveness of gene therapy techniques. Panteli's expertise and dedication to his field have made him a valuable asset to his company and the broader scientific community.

Collaborations

Jan Panteli collaborates with talented individuals in his field, including his coworker Ying Jing. Their combined efforts contribute to the advancement of biotechnological innovations and the development of new therapeutic strategies.

Conclusion

Jan Panteli's contributions to the field of biotechnology through his patents and work at Ultragenyx Pharmaceutical Inc. highlight his role as a key innovator. His advancements in transfection reagents and viral vector production are essential for the future of genetic engineering and therapeutic applications.